- Q4 2023 Xeris Biopharma Holdings Inc Earnings Call TranscriptMar 06, 2024$2.48 (-19.48%)Earnings
- Xeris Biopharma Holdings Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Q3 2023 Xeris Biopharma Holdings Inc Earnings Call TranscriptNov 09, 2023$1.81 (-8.84%)Earnings
- Q2 2023 Xeris Biopharma Holdings Inc Earnings Call TranscriptAug 08, 2023$2.58 (+3.61%)Earnings
- Q1 2023 Xeris Biopharma Holdings Inc Earnings Call TranscriptMay 09, 2023$2.73 (+13.75%)Earnings
- Q4 2022 Xeris Biopharma Holdings Inc Earnings Call TranscriptMar 08, 2023$1.35 (-11.76%)Earnings
- Xeris Biopharma Holdings Inc at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Q3 2022 Xeris Biopharma Holdings Inc Earnings Call TranscriptNov 09, 2022$1.48 (-1.33%)Earnings
- Xeris Biopharma Holdings Inc XP-8121 Call TranscriptOct 20, 2022
- Q2 2022 Xeris Biopharma Holdings Inc Earnings Call TranscriptAug 10, 2022$1.93 (+13.53%)Earnings
- Q1 2022 Xeris Biopharma Holdings Inc Earnings Call TranscriptMay 11, 2022$1.64 (-8.38%)Earnings
- Q4 2021 Xeris Biopharma Holdings Inc Earnings Call TranscriptMar 10, 2022$2.62 (+6.07%)Earnings
- Q3 2021 Xeris Biopharma Holdings Inc Earnings Call TranscriptNov 10, 2021$1.9 (-3.06%)Earnings
Xeris Biopharma Holdings Inc XP-8121 Call Transcript
Good morning, everyone, and welcome to today's Top Line Phase I Study Results of XP-8121. My name is Drew, and I'll be coordinating your call today. (Operator Instructions). I'm now going to hand over to Allison Wey, Senior Vice President, Investor Relations and Corporate Communications, to begin. Please go ahead.
Thank you, Drew. Good morning and thank you for joining us to discuss the results of our Phase I study of XP-8121. A press release was issued earlier this morning and can be found on our website. We are joined today by Paul Edick, Chairman and CEO; and Ken Johnson, Senior Vice President of Global Development and Medical Affairs. Paul will provide opening remarks, and Ken will review the study design and results, and then we'll open the line for questions.
Before we begin, I would like to remind you that this call will contain forward-looking statements concerning Xeris' business practices, Xeris' future expectations, plans, prospects, clinical approvals,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)